ClinicalTrials.gg
RecruitingNCT01694940NAMDCUpdated Feb 4, 2026

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

An observational study in Mitochondrial Disorders, Mitochondrial Genetic Disorders and Mitochondrial Diseases, sponsored by Columbia University. Recruiting at 17 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Columbia University · Observational

From the registry’s dates

  • Started Jan 2011; still recruiting 15 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Study summary

The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.

Read the detailed description

Mitochondrial diseases comprise a group of relatively rare (\~1 in 5000 adults) but very serious genetic disorders. Mitochondria are often called the "powerhouses of the cell" because they provide the energy our cells need to live. Mitochondria have their own DNA (mtDNA), but they also rely on DNA from the nucleus (nDNA). Mitochondrial diseases are caused by mutations in either mitochondrial or nuclear DNA that result in poorly functioning mitochondria. This can cause a variety of symptoms including muscle weakness, seizures, mental retardation, dementia, hearing loss, blindness, strokes, diabetes, and premature death. Most mitochondrial diseases are progressive, and we are unable to cure most of these diseases with currently available treatments.

Research into mitochondrial diseases has been hampered by the low frequency of these disorders and by under-diagnosis by clinicians. This has hindered patient recruitment for research studies and clinical trials. The North American Mitochondrial Disease Consortium (NAMDC) was established to help surmount these issues. Led jointly by Drs. Michio Hirano and Salvatore DiMauro, NAMDC is a consortium of several clinicians and researchers with an interest in mitochondrial disease research in the United States and Canada.

By creating a mechanism for the sharing of patient samples with researchers, data and patient contact information, NAMDC will make it easier to conduct clinical and basic laboratory research.

Patient information will be shared through the use of the "Patient Data Registry," a specially-designed database, and patient tissue samples will be shared through the use of the "Patient Sample Biorepository", a storage facility in which patient-derived biological samples will be maintained. The Registry and the Biorepository will hopefully accelerate progress in the understanding and treatment of mitochondrial disease.

Patients can enroll at any of the NAMDC member sites. A web-based remote enrollment is also available at www.namdc.org for eligible patients who reside far from any of the NAMDC participating sites.

02

Conditions studied

  • Mitochondrial Disorders
  • Mitochondrial Genetic Disorders
  • Mitochondrial Diseases
  • Disorder of Mitochondrial Respiratory Chain Complexes
  • Deletion and Duplication of Mitochondrial DNA

Keywords

  • mitochondrial disorders
  • Mito Disease
  • Mitochondria
  • Mitochondrial disease
  • Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke (MELAS) Syndrome
  • Myoclonic Epilepsy with Ragged Red Fibers (MERRF)
  • Leber Hereditary Optic Neuropathy (LHON)
  • Leigh Syndrome
  • Neuropathy, ataxia, and retinitis pigmentosa (NARP)
  • Kearns Sayre syndrome
  • Alpers Huttenlocher
  • Pearson
  • Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE)
  • Barth Syndrome
  • Coenzyme Q (CoQ) Deficiency
  • Chronic progressive external ophthalmoplegia (CPEO)
  • DAD
  • Diabetes and Deafness
  • Encephalopathy
  • Encephalomyopathy
  • Familial Bilateral Striatal Necrosis (FBSN)
  • Hepatocerebral Disease
  • Leukoencephalopathy
  • Maternally Inherited Leigh Syndrome (MILS)
  • Complex I Deficiency
  • Complex II Deficiency
  • Complex III Deficiency
  • Complex IV Deficiency
  • Complex V Deficiency
  • mitochondrial DNA depletion syndrome
  • mtDNA depletion syndrome
03

In context

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 80 across 65 observational studies indexed under Mitochondrial Diseases.

Browse Mitochondrial Diseases studies →

Lead sponsor

Columbia University is the lead sponsor of 1,136 studies on the registry; 195 are open to participants now.

Of its 180 completed or terminated interventional studies of FDA-regulated products, 148 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with known mitochondrial disorders. People at risk of carrying a mitochondrial DNA mutation Patients with abnormal mitochondrial function

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with or suspected to have a mitochondrial disorder
  • Adult carriers of known mitochondrial DNA mutations
  • Patients with laboratory analysis indicative of a mitochondrial disorder.
  • Medical information and tissue samples are also accepted from deceased individuals who fulfill the above criteria.

Exclusion criteria

Exclusion Criteria:

  • Patients not suspected of having a mitochondrial disorder
  • Patients not suspected of carrying a mitochondrial DNA or nuclear DNA mutation that affects mitochondrial function.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Mitochondrial Disease Patients

    Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.

06

What researchers measure

Primary outcomes

  1. There is no primary outcome measure for this study

    This is a registry protocol and therefore there is no primary outcome measure for this study.

    Time frame: end of study

07

Study locations

17 of 17 sites recruiting
  • University of California San Diego
    San Diego, California 92103, United States
    Recruiting
    • Richard Hass, MD · Contactrhass@ucsd.edu · 18588226700
    • Robert Naviaux, MD · Contactnaviaux@ucsd.edu · 16195432904
    • Robert Naviaux, MD · Principal investigator
    • Richard Haas, MD PhD · Principal investigator
  • Lucile Packard Children's Hospital
    Stanford, California 94305, United States
    Recruiting
    • Gregory Enns, MD · Contact1-650-723-6858
    • Gregory Enns, MD · Principal investigator
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
    Recruiting
    • Johan Van Hove, MD PhD MBA · Contact3037242351
    • Abigail Collins, MD · Contactabibail.collins@ucdenver.edu · 7207776895
    • Johan Van Hove, MD PhD MBA · Principal investigator
    • Abigail Collins, MD · Principal investigator
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Andrea Gropman, MD · Contactagropman@cnmc.org · 202-476-3511
    • Andrea Gropman, MD · Principal investigator
  • University of Florida
    Gainsville, Florida 32610, United States
    Recruiting
    • Peter Stacpole, MD · Contactstacpool@gcrc.ufl.edu · 13522658909
    • Peter Stacpole, MD · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Amel Karaa, MD · Contactakaraa@partners.org · 6173556117
    • Amel Karaa, MD · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
    Recruiting
  • Columbia University Medical Center
    New York, New York 10032, United States
    Recruiting
    • Michio Hirano, MD · Contactnamdc@columbia.edu · 2123051048
    • Michio Hirano, MD · Principal investigator
  • Virtual Site (Remote enrollment)
    New York, New York 10032, United States
    Recruiting
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
    Recruiting
    • Bruce Cohen, MD · Contactbcohen@chmca.org · 13305436048
    • Bruce Cohen, MD · Principal investigator
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Sumit Parikh, MD · Contactparikhs@ccf.org · 12164441994
    • Sumit Parikh, MD · Principal investigator
  • Case Western Reserve University
    Clevland, Ohio 44106, United States
    Recruiting
    • Charles Hoppel, MD · Contactcharles.hoppel@case.edu · 12163683147
    • Douglas Kerr, MD · Contactdouglas.kerr@case.edu · 12168443661
    • Charles Hoppel, MD · Principal investigator
    • Douglas Kerr, MD PhD · Principal investigator
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Marni J Falk, MD · Contactfalkm@email.chop.edu · 2155904564
    • Marni J Falk, MD · Principal investigator
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Amy Goldstein, MD · Contact1-412-692-5520
    • Amy Goldstein, MD · Principal investigator
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
    • William Craigen, MD · Contactwcraigen@bcm.edu · 17137988305
    • Fernando Scaglia, MD · Contactfscaglia@bcm.tmc.edu · 18328224280
    • William Craigen, MD · Principal investigator
    • Fernando Scaglia, MD · Principal investigator
  • Seattle Children's Hospital and Regional Medical Center
    Seattle, Washington 98105, United States
    Recruiting
  • McMaster University
    Hamilton, Ontario ON L8N 3Z5, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized participant data is available upon request and approval by the NAMDC Data Use Committee.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01694940
Responsible party
Michio Hirano, MD (Professor of Neurology, Columbia University) — Principal investigator
First posted
Sep 27, 2012
Start date
Jan 31, 2011
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 4, 2026

Study contacts

Michio Hirano, MD
Contact
NAMDC@columbia.edu
12123051048
Kristin Engelstad, MS
Contact
NAMDC@columbia.edu
12123056834
Michio Hirano, MD
study director · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion